A novel orally available Syk/Src/Jak2 inhibitor, SKLB-850, showed potent anti-tumor activities in B cell lymphoma (BCL) models
Nannan Zhang(Sichuan University), Shengyong Yang(Sichuan University)
Cited by 7
Related Papers
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
|Signal Transduction and Targeted Therapy|2021|1.6k
Generative deep learning enables the discovery of a potent and selective RIPK1 inhibitor
|Nature Communications|2022|98
The bromodomain protein BRD4 positively regulates necroptosis via modulating MLKL expression
|Cell Death and Differentiation|2019|39